Increasing evidence from our group as well as other investigators have implicated a role for PRL3 in different hematological malignancies, including multiple myeloma (MM), AML, chronic myeloid leukemia (CML), and acute lymphoblastic leukemia (ALL) [15–17, 43–45]. The gene discussed is PTP4A3; the disease is plasma cell myeloma.